SUNNYVALE, Calif., Oct. 20 /PRNewswire/ -- Accuray, Inc., (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that it ranked number 113 on Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the period from 2005–2009. Accuray grew 944 percent during the fiscal period of 2005-2009.
"With a 244 percent increase in patients treated from 2005-2009 and more than 200 CyberKnife sites across the world, we are well positioned to see continued utilization and growth of CyberKnife radiosurgery in the year ahead," said Euan S. Thomson, president and chief executive officer at Accuray. "These achievements are a testament to the hard work and dedication of Accuray employees to make the CyberKnife System an accessible and best-in-class radiosurgery treatment for the many patients diagnosed with malignant and benign tumors every year."
"Accuray and the other 2010 Technology Fast 500™ winners forged ahead in a challenging economic environment to realize exceptional growth," said Phil Asmundson, vice chairman and Deloitte's U.S. technology, media and telecommunications leader. "Deloitte commends Accuray for this impressive accomplishment."
"Accuray has proved itself to be one of the fastest growing tech companies in North America, and we are proud to honor them as one of the 2010 Technology Fast 500™," said Mark Jensen, managing partner, venture capital services, Deloitte & Touche LLP.
Accuray previously ranked 155 as a Technology Fast 500™ award winner for 2009.
For additional detail on the Technology Fast 500™ including selection and qualifying criteria, visit www.fast500.com.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to deliver more than 100,000 treatments worldwide and more than 206 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to revenue growth, utilization growth and radiation field growth are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2009 fiscal year, our quarterly report on Form 10-Q filed on May 6, 2010, and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
As used in this document, "Deloitte" means Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Euan Thomson, Ph.D.
|SOURCE Accuray Incorporated|
Copyright©2010 PR Newswire.
All rights reserved